FL-496 / Canget - LARVOL DELTA

FL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination. (PubMed, J Exp Clin Cancer Res) - "Together, these results indicate that FL496 is a promising anti-MPM small molecule, and its high anti-MPM potential is worthy of being further explored as a monotherapeutic agent to treat MPM patients in clinical trials."

IO biomarker • Journal • Genetic Disorders • Immunology • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Osteosarcoma • Pleural Mesothelioma • Primary Immunodeficiency • Sarcoma • Solid Tumor • BCL2 • BCL2L1 • BIRC5 • CASP3 • CDKN1A • DDX5 • MCL1 • TP53

Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. (PubMed, J Exp Clin Cancer Res) - "We then present our data to show the anticancer drug FL118 modulation of these protein targets and RCC cell/tumor growth. Finally, we include additional data to show a promising FL118 analogue (FL496) for treating the specialized type 2 papillary RCC."

Biomarker • Journal • Review • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • ABCG2 • BIRC5 • EPAS1 • ERCC6 • HIF1A • KRAS • MCL1 • MDM2 • MDM4 • XIAP